wook, between the representatives of an Activist investor as they were called by CEO King and Dr. Wolchok of Memorial Sloan Kettering I think that I will go with Memorial Sloan Kettering as far as Bavituximab is concerned.
And NCCN runs 3 clinical trials in t America's 20+ Top Notch centers and if Bavituximab was that worthless they wouldn't do that.
Furthermore be aware for those that want you to believe that it is worthless. Well if it is I'll take it of there hands for free. Let's then see if it is still worthless.
And how did that same Mr White that is the co-signer of the letters to shareholder promise us to monetise something that is worthless?
NOT PUTTING ANY VALUE ON BAVITUXIMAB is their way to AVOID that we would EVER say they stole it for breadcrumbs while they knew the value. The letters would be prove against themselves.
Market Data 
Markets 
AI
